Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Calretinin ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA
  • Other names:29 kDa calbindin
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New REA611/96R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA

Applications

Serum, Plasma

Sample Requirements

15 μl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box)

Calibration Range

0.25 ng/ml – 4.0 ng/ml

Summary

Features

  • In the US, for research use only!
  • Sample Preparation: 60 min shaking at room temperature
  • ELISA: 4.5 hours incubation at room temperature

Research topic

Oncology

Summary

For some time now, the production and application of asbestos has been banned in more than 55 countries in the world. However, the number of asbestos-associated cancers – mainly malignant lung cancer and mesothelioma – is still high. Due to long latency of the disease and ongoing production and application of asbestos in several countries, no substantial improvement is expected. Detecting tumors early – preferably at stages without clinical symptoms - might improve the chances for a curative therapy. In collaboration with scientists of the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-University Bochum (IPA) the DLD Diagnostika GmbH developed a promising method based on calretinin as a biomarker for early detection – especially of mesothelioma – in plasma and serum samples. Currently, calretinin is one of the best available markers for the detection of mesothelioma.

References to Summary

References to Calretinin

  • Johnen G., Gawrych K., Raiko I., Casjens S., Pesch B., Weber D. G., Taeger D., Lehnert M., Kollmeier J., Bauer T., Musk A. W., Robinson B. W. S., Brüning T., Creaney J. Calretinin as a blood-based biomarker for mesothelioma BMC Cancer 2017; 17: 386
  • Casjens S, Weber DG, Johnen G, et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population based cohort study. BMJ Open 2017;7:e017104.doi:10.1136/bmjopen-2017-017104
  • Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, Scherpereel A, Brüning T, Johnen G. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242
  • Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014; 1844: 874-883
  • Calretinin ELISA: A New Assay for the Detection of Mesothelioma in Blood Samples. Georg Johnen, Irina Raiko, Ingrid Sander, Daniel G. Weber, Monika Raulf-Heimsoth, Adrian Gillissen, Jens Kollmeier, Klaus-Michael Müller, Arnaud Scherpereel, Thomas Brüning (data on file)
Related Products Documents